Topical testosterone for lichen sclerosus.
Twenty-three patients diagnosed as lichen sclerosus with colposcopic directed biopsy were given topical testosterone as a first line therapy. The overall remission rate was found to be 87.7%; 8.7% of the patients experienced undesirable androgenic side effects. Of the three patients who did not respond satisfactorily to testosterone treatment, two had alcohol injection to the vulva and one had vulvar denervation.
Ayhan
A
A
Department of Obstetrics and Gynecology, Hacettepe University, Ankara, Turkey.
Urman
B
B
Yüce
K
K
Ayhan
A
A
Gököz
A
A
D000287:Administration, Topical; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D011374:Progesterone / Q000008:administration & dosage; D011539:Pruritus Vulvae / Q000188:drug therapy; D013739:Testosterone / Q000008:administration & dosage*; D014845:Vulvar Diseases / Q000188:drug therapy*; D007724:Vulvar Lichen Sclerosus / Q000188:drug therapy
D013739:Testosterone; D011374:Progesterone